| CME |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$2.93 vs. cons $2.897 |
MEDIUM |
| CME |
Report |
Revenue |
BEAT |
pred ~$1.700B vs. cons $1.678B |
MEDIUM |
| CME |
Report |
ADV |
BEAT |
pred ~30.70M vs. cons 30.263M |
MEDIUM |
| CME |
Guide |
FY2026 adjusted operating expense |
UNKNOWN |
guide ~$1.695B vs. cons UNVERIFIED |
LOW |
| CME |
Guide |
FY2026 demand/RPC commentary |
UNKNOWN |
maintain constructive demand tone but retain mix/RPC caution vs. cons UNVERIFIED |
LOW |
| CME |
Return |
Day-1 residual (stock − beta × S&P 500) |
-0.5% |
— |
LOW |
| CME |
Return |
5-day cumulative residual |
-1.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained cost guide does not resolve forward revenue/RPC risk |
LOW |